Differences

This shows you the differences between two versions of the page.

--- ciaran_lawlor [2023/06/15 01:59]
liam
+++ ciaran_lawlor [2023/07/10 17:50] (current)
liam
@@ Line 7: / Line 7: @@
 ===== History =====
-==== COVID-19 ====
+==== Education ====
+Lawlor graduated from [[Maynooth University]], completing a 3 month lab placement at [[Kings College London]]. He then received credentials from the [[Royal College of Surgeons in Ireland]] (RCSI).((//Ciaran Lawlor.// LinkedIn. Retrieved June 14, 2023, from https://www.linkedin.com/in/ciaran-lawlor-919546b/))
+==== Career ====
+From October 2011 to November 2013, Lawlor worked at [[pharmaceutical_companies:PULMATRiX]], focusing on "formulation development for pre-clinical studies with small molecules, antibiotics, macromolecules and new chemical entities."((//Ciaran Lawlor.// LinkedIn. Retrieved June 14, 2023, from https://www.linkedin.com/in/ciaran-lawlor-919546b/))
+He then went to work at [[pharmaceutical_companies:Moderna]], where he "helped build internal capabilities on nanoparticle formulation including growing formulation team and acting as lead delivery technology scientist on key strategic partnerships."
+In January 2016, Lawlor was hired at the [[Boston Consulting Group]] (BCG), where he was quickly promoted to Principal.
+=== COVID-19 ===
 Lawlor co-authored a paper titled "The Near-Term Outlook for COVID-19 Therapeutic Treatments" published by the [[Boston Consulting Group]] on May 8, 2020. The paper presented a favourable outlook for the use of the experimental drug [[remdesivir]] over a variety of other options to treat [[COVID-19]]. Lawlor's co-authors were [[Jordon Walker]], [[Ahad Wahid]] and [[Josh Kellar]].((Lawlor, C., Wahid, A., Walker, J., & Kellar, J. (2020). //The Near-Term Outlook for COVID-19 Therapeutic Treatments.// Boston Consulting Group. https://web.archive.org/web/20230422204237/https://web-assets.bcg.com/img-src/BCG-The-Near-Term-Outlook-for-COVID-19-Therapeutic-Treatments-May-2020_tcm9-246799.pdf))
 A follow-up article was published on May 14, 2020, titled "The Timelines and Implications for COVID-19 Vaccines". It was co-authored with Kellar, Wahid, [[Emily Serazin]], [[Andrew Rodriguez]] and [[Philip Berk]].((Lawlor, C., Kellar, J., Serazin, E., Rodriguez, A., Berk, P., & Wahid, A. (2020, May 14). //The Timelines and Implications for COVID-19 Vaccines.// Boston Consulting Group. http://archive.today/2023.06.14-235609/https://www.bcg.com/en-ca/publications/2020/covid-vaccines-timelines-implications))
+In April 2021, Lawlor left BCG to become Chief Operating Officer of [[pharmaceutical_companies:ReNAgade Therapeutics]].((//Team.// ReNAgade Therapeutics. Retrieved June 14, 2023, from https://web.archive.org/web/20230614231455/https://renagadetx.com/team/))
+===== Patents =====
+  * [[http://archive.today/2023.06.15-003024/https://patents.google.com/patent/US11235112B2/en?q=(Inhalable+dry+powders)&oq=Inhalable+dry+powders|Inhalable dry powders]]
+  * [[https://patents.google.com/patent/WO2016118724A1/en?oq=2016118724|Lipid nanoparticle compositions]]
 ===== External links =====
+  * [[http://covidtruthinitiative.ca/e/en/Individuals/Ciaran-Lawlor|COVID Truth Initiative]]
   * [[https://www.linkedin.com/in/ciaran-lawlor-919546b/|LinkedIn]]